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Conclusion: Dose escalated radiotherapy for node positive 
locally advanced cervical cancer at primary diagnosis or at 
nodal recurrence using a SIB results in acceptable rates of 
acute and late toxicity. And although our small size 
population, the present results contribute that the SIB 
technique is a good treatment for the patients with nodal 
regional disease. 
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Purpose or Objective: To determine the maximum tolerated 
dose (MTD) and dose-limiting toxicity (DLT) of weekly PTX 
and DDP concurrent postoperative radiotherapy in Chinese 
women with high- and intermediate-risk early cervical 
cancer. 
 
Material and Methods: Women with high risks postoperative 
cervical carcinoma, negative para-aortic nodes, KPS≥60 were 
eligible. Pelvis RT (6/10MV-X, 3D-CRT, DT40Gy/20f, para-
metrial boost 10~20Gy/5~10f) was followed by 2~4f 
brachytherapy applications (192Ir，5Gy/f). Concurrent 
weekly chemotherapy was started at DDP 20mg/m2/W and 
PTX 10mg/m2/W, and escalated in three-patient cohorts 
according to 3+3 methods. Serious Adverse Event (SAE) was 
defined as grade 4 hematologic toxicity (excluding anemia) 
within 30 days of treatment, or grade 3/4 non-hematologic 
toxicity (excluding alopecia, nausea/anorexia, vomiting). 
Table 1.Chemotherapy Dose Level Schema 
 
 
 
Results: 25 patients were enrolled and treated over seven 
doses levels until dose-limiting toxicity (DLT) was reached. 
Median age was 48 years (range, 34-66). All of patients 
finished RT in 6 weeks. Grade 3/4 non-hematologic toxicities 
were diarrhea and observed in two patients (4 cycles, DLT) at 
level VII. 3/4°hematologic, principally neutropenia, and 
occurs late cycles. One grade IV WBC and NEUT was observed 
at dose level VI but not seen in three additional patients. No 
one was delayed treatment time by concurrent 
chemotherapy. The 1st patient finished 3 cycles due to 2° 
diarrhea at level I; 1 patient for 5 cycles at level III; 4 
patients finished 6 cycles at level VII. Median follow-up is 56 
months. 2 recurrent or metastasis patients have died. 1 
patient has died of acute pneumonia (30.5 months). Late 
toxicities did not appear during follow-up. 
 
Conclusion: Combination PTX and DDP administered 
concurrently with pelvic EBRT can be safely administered at 
the MTD of DDP 35 mg/m2 and PTX 30 mg/m2 weekly for six 
cycles in Chinese women with postoperative cervical cancer. 
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Purpose or Objective: In order to verify the results in a 
population of patients (pts) staged with CT and MR and 
treated with HDR BT and modern EBRT techniques, we review 
our experience in the treatment of vaginal or pelvic 
recurrences of endometrial adenocarcinoma. 
 
Material and Methods: April 1997-October 2012 181 pts. 161 
(89%) endometrioid, 12 adenosquamous and 8 clear cell. 30% 
G1, 42% G2, 25% G3, 10% G unknown. Median age 70 years 
(range 41-83). First line treatment: surgery alone 134 pts, 
surgery plus EBRT 27 pts, surgery plus CTH 18 pts and EBRT 
alone 2 pts. TAH&BSO 145 (80%) pts (36 with pelvic lymph-
node sampling), Piver II and pelvic lymphadenectomy 36 pts. 
Median time to relapse 27 months (range 3-221). 126 pts had 
vaginal recurrences (66 limited to the dome and 60 with 
extension to the mid and/or lower third). 45 had a pelvic 
mass (31 centropelvic, 14 lateral wall); 10 pts had a vaginal 
recurrence with synchronous extra pelvic disease (6 lung mts 
and 4 LA nodes). 27 pts had prior adjuvant EBRT after 
surgery: dose range 32.4-57 Gy; no pts had received VBT. 
VBT: we use vaginal, shielded cylinders, Miami applicator and 
vaginal ovoid; interstitial BT in addition to VBT in 11 patients 
with sub urethral infiltration. HDR BT alone in 68 pts and in 
combination with EBRT in 113 pts. EBRT doses: range 30.6-
50.4 Gy. VBT HDR doses: range 15-25 Gy when used in 
combination with EBRT and 30-44 Gy when used alone; 
fraction size: range 4-6 Gy. Interstitial BT: 2-2.5 Gy fr, 2 
frs/day, total dose 20-25 Gy. Prescriptions for VBT were at 
depths ranging between 5 and 10 mm, according with the 
lesion size. 
 
Results: Clinical CR 170 pts (94%). Median f-up 102 months 
(range 32-168). 38 pts DOD (14 lung mts, 8 with peritoneal 
mts without local failure and 16 with local failure, peritoneal 
and/or lung mts); 18 AWD and 125 (69%) NED. 27 local 
recurrences: median time to relapse 20 months (range 5-36); 
we retread, 12 of these, with further VBT HDR and five 
achieved a new CR. Late complication: 98 pts (54%) G0, 45 
pts vaginal stenosis and/or severe mucosal dystrophy, 18 mild 
proctitis (G1), 5 severe proctitis (G2), 2 (G3) small bowel 
fistula that required surgery; 12 urine incontinence. Two 
developed a severe necrosis of the mucosa of the inferior 
third of the vagina that resolved after medical therapy. 
 
Conclusion: Treatment of local recurrences of endometrial 
adenocarcinoma in a population of pts staged with CT and MR 
and treated with HDR BT and modern EBRT is effective and 
safe; severe complications are rare even in pre-irradiated 
pts. 
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Purpose or Objective: Vaginal cancer is the most rare 
gynecological malignancy. Consequently, few dose effect 
data are available. The main objective of our retrospective 
study was to analyze the outcome of all patients treated at 
our department with definitive (chemo-)radiotherapy for 
primary vaginal cancer, with a focus on local failure. 
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Material and Methods: Thirty-four patients were included in 
a period from 1994 until 2013. Patients’ charts were 
reviewed to obtain patients’, treatment and tumor 
characteristics. DVH parameters were analyzed after 
reconstruction of the original brachytherapy plan plus 
delineation of intermediate risk CTV (CTVIR) and organs at 
risk. The target volume at time of BT was the GTVres and 
was defined by the treating doctor based on clinical 
examination and CT scan. The CTVIR was defined by the 
tumor extension at time of diagnosis. Survival rates were 
calculated using the Kaplan-Meier method. Morbidity was 
scored by CTCAE v3.0. 
 
Results: Nine (26%) patients had FIGO stages I; 13 (38%) II; 5 
(15%) III and 7 (21%) IVA. Median age at diagnosis was 68 
years (33-91). Median follow-up was 37 months (3-224). 
Thirty-two patients received whole pelvic external beam 
radiotherapy (EBRT) to a median dose of 46 Gy (45-50.4 Gy), 
followed by BT in 31 patients; two patients received BT 
alone. The median D90 and D98 of the GTVres were 68 Gy 
and 67 Gy respectively, with a median V100 of 88%. The 
median D90 and D98 of the CTVIR were 65 Gy and 61 Gy 
respectively, with a median V100 of 62%. Complete remission 
at 3 months was achieved in all but one patient. Overall 
survival (OS) rates at 2- and 5-years were respectively 76% 
and 41%. Eight (24%) patients had any grade ≥3 toxicity. Local 
recurrences were seen in seven (21%) patients of whom three 
had an isolated local recurrence. Patients’ and treatment 
characteristics of this group are shown in Table 1. Although 
the coverage of the GTVres seemed adequate, in retrospect 
it was often disputable if the tumor at BT was fully covered 
due to poor visibility of the tumor on CT scan. 
 
 
 
 
Conclusion: The combination of EBRT and BT with or without 
concomitant chemotherapy provides reasonable outcomes in 
terms of tumor control and toxicity. However, there is still 
room for improvement. This study was too small to illustrate 
clear dose-effect relationships. In general, the prescribed 
dose on target at time of BT (GTVres) seemed low. In 
addition, coverage of the CTVIR was poor, which can however 
be explained by the fact that until recently our target at BT 
was exclusively based on GTVres. Finally, the use of MRI at 
time of BT seems necessary to better define the target. 
 
EP-1331 
Cancer of uterine cervix: PET-CT, IMRT and HDR. 
M. Garcia-Aranda1, X. CHEN
1Hospital universitario HM Sanchinarro, Radiation Oncology 
Department, Madrid, Spain 
1, A. Montero1, J. Valero1, R. 
Alonso2, D. Zucca3, R. Ciervide1, M. Lopez1, B. Alvarez1, S. 
Payano1, E. Sanchez1, O. Hernando2, C. Rubio1 
2Hospital universitario HM Puerta del Sur, Radiation 
Oncology Department, Madrid, Spain 
3Hospital universitario HM Sanchinarro, Medical Physics 
Department, Madrid, Spain 
 
Purpose or Objective: To evaluate the treatment results, 
and complication rates in patients with locally advanced 
cervical cancer after external beam radiotherapy (EBRT) and 
high-dose rate (HDR) brachytherapy with dose escalation. 
 
Material and Methods: All patients with locally advanced 
cervical cancer (FIGO: IB 7 patients, II 10 patients, III 7 
patients, IV 4 patients) treated with radical radiotherapy in 
our center from 2007 to October 2015 were reviewed. 
Twenty eight patients were treated with EBRT using 
intensity-modulated radiation therapy (IMRT) technique 
following by HDR brachytherapy +/- chemotherapy. 
Planification included CT (50%) or PET-CT (50%) for GTV 
delineation. The most common prescription was 50.4 Gy 
(1.8Gy per fraction) for pelvic lymph nodes +/- paraaortic 
lymph node with concomitant boost up to 60, 48 Gy (2,16Gy 
per fraction) for macroscopic nodal disease and parametrium 
affectation. HDR brachytherapy was applied using tandem (25 
Gy in 5 fractions) in most patients. Toxicity was assessed 
according to RTOG-EORTC criteria. All statistical analysis was 
performed using SPSS vs 22.0. 
 
Results: There was no grade 3 acute toxicity associated with 
EBRT. Only one case of grade 4 acute toxicity was observed 
after HDR gynecological brachytherapy. The median age was 
51 years (range 39 – 81). The median of follow up was 30 
months (range 4 – 85). The actuarial progression-free survival 
was 77% at 36 months. Median time to local progression has 
not been reached. The median overall survival was 30 (range 
4-85) month. 
 
Conclusion: Radical radiotherapy +/- chemotherapy is still a 
standard treatment in locally advanced uterine cervical 
cancer with good local control and global survival. Dose 
escalation is possible using PET-CT and IMRT which allow 
better conformation and better tolerance.  
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Purpose or Objective: To determine clinical efficacy and 
toxicity of weekly nimotuzumab plus cisplatin concurrent 
with intensity-modulated radiotherapy in Chinese women 
with locally advanced cervical cancer. 
 
Material and Methods: Between December 2013 and July 
2015, a total of 27 patients with primary carcinoma of the 
cervix, FIGO stage IB1 to IVa, squamous cell carcinomas 
confirmed by histology were enrolled into this study. 26 
patients received intensity modulated radiotherapy and 5 ~ 6 
fractions HDR brachytherapy, 1 patient received intensity 
modulated radiotherapy followed by surgery because she had 
rectum carcinoma at the same time. Chemotherapy scheme 
was 200 mg nimotuzumab and 40 mg/m2 cisplatin weekly for 
six cycles. 2 patients (ages: 78 ~ 79) received only 200 mg 
nimotuzumab weekly for six cycles. The patients were 
